Scientific Reports · 2017 · 32 citations · 33 references
MedicineMedicinal ChemistryOncologyCancer PharmacologyChemotherapyMolecular OncologyCoordination ChemistryRedox ChemistryAnticancer ActivityAnticancer ChemotherapyAnticancer Mechanism Of ActionKidney Tissue ModelsLiver Tissue ModelsOxidation State AssignmentOxidation State Dependence
Abstract Ruthenium complexes are promising candidates for anticancer agents, especially NKP-1339 (sodium trans -[tetrachloridobis(1 H -indazole)ruthenate(III)]), which is on the edge to clinical applications. The anticancer mechanism seems to be tightly linked to the redox chemistry but despite progress in human clinical trials the in vivo Ru oxidation state and the coordination of Ru remains unclear. The Ru-based anticancer drug NKP-1339 was studied applying XANES (Cl K- and Ru L 2,3 -edges) in tumor, kidney and liver tissue of a SW480 bearing mouse. Based on coordination charge and 3D XANES plots containing a series of model compounds as well as pre-edge analysis of the ligand Cl K-edge it is suggested that NKP-1339 remains in its +III oxidation state after 24 hours and at least one of the four chlorido ligands remain covalently bound to the Ru ion showing a biotransformation from Ru III N 2 Cl 4 to Ru III Cl x (N/O) 6−x (X = 1 or 2).
33
NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application
Robert Trondl, Petra Heffeter, Christian R. Kowol et al. · Chemical Science · 2014 · 659 citations · Full text
Medicine, Oncology, Pharmacology +14
Alberta Bergamo, R Gagliardi, V. Scarcia et al. · Journal of Pharmacology and Experimental Therapeutics · 1999 · 156 citations
Medicine, Oncology, Pharmacology +15
Aleksandar Bijelic, Sarah Theiner, Bernhard K. Keppler et al. · Journal of Medicinal Chemistry · 2016 · 123 citations · Full text